HUM · 10-Q · 2026Q3 · Full report

Medicare GLP-1 Bridge Program

HUMANA INC · 2026-11-06 · Importance 38 · Surprise 60

Effective July 1, 2026, Humana began serving as central processor for a time-limited CMS demonstration giving eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight management outside the Part D benefit coverage and payment flow. Humana administers prior authorizations, processes claims, facilitates pharmacy payments, invoices participating manufacturers, and conducts reconciliation and reporting, while CMS bears the underlying drug-cost risk. At September 30, 2026, the program generated $0.7 billion of manufacturer rebate receivables and a $2.7 billion Due to CMS settlement liability; net receipts from contract deposits were $2.0 billion for both the three- and nine-month periods ended September 30, 2026.

Key facts

• Effective July 1, 2026, Humana began serving as central processor for the time-limited CMS Medicare GLP-1 Bridge demonstration, administering prior authorizations, claims, pharmacy payments, manufacturer invoices, reconciliation, and reporting. source
• At September 30, 2026, Humana had $0.7 billion of GLP-1 Program manufacturer rebate receivables in other current assets and $2.7 billion of related Due to CMS settlement liability in trade accounts payable and accrued expenses. source
• Under the Medicare GLP-1 Bridge Program, CMS bears the underlying drug-cost risk and Humana does not assume insurance risk for related claims. source
• Net receipts from contract deposits related to the Medicare GLP-1 Bridge Program were $2.0 billion in both the three and nine months ended September 30, 2026. source